spironolactone has been researched along with Hypertension, Renovascular in 12 studies
Spironolactone: A potassium sparing diuretic that acts by antagonism of aldosterone in the distal renal tubules. It is used mainly in the treatment of refractory edema in patients with congestive heart failure, nephrotic syndrome, or hepatic cirrhosis. Its effects on the endocrine system are utilized in the treatments of hirsutism and acne but they can lead to adverse effects. (From Martindale, The Extra Pharmacopoeia, 30th ed, p827)
spironolactone : A steroid lactone that is 17alpha-pregn-4-ene-21,17-carbolactone substituted by an oxo group at position 3 and an alpha-acetylsulfanyl group at position 7.
Hypertension, Renovascular: Hypertension due to RENAL ARTERY OBSTRUCTION or compression.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Losartan treatment decreased systolic pressure and yellow-red collagen fiber content in all areas, whereas spironolactone treatment decreased green collagen fiber content without decreasing systolic pressure." | 5.29 | Left ventricular fibrosis in renovascular hypertensive rats. Effect of losartan and spironolactone. ( Appay, MD; Bariety, J; Heudes, D; Hinglais, N; Michel, JB; Nicoletti, A; Philippe, M; Sassy-Prigent, C, 1995) |
| "Spironolactone, however, was able to prevent myocardial fibrosis in RHT and aldosterone models of acquired arterial hypertension irrespective of the development of LVH and the presence of hypertension." | 5.29 | Antifibrotic effects of spironolactone in preventing myocardial fibrosis in systemic arterial hypertension. ( Brilla, CG; Matsubara, LS; Weber, KT, 1993) |
| "Renovascular hypertension is one of the common causes of secondary hypertension." | 1.48 | Unilateral renal artery stenosis presenting as acute flaccid paralysis: a rare presentation. ( Banerjee, S; Garg, K; Rajput, R; Singh, PK, 2018) |
| "Losartan treatment decreased systolic pressure and yellow-red collagen fiber content in all areas, whereas spironolactone treatment decreased green collagen fiber content without decreasing systolic pressure." | 1.29 | Left ventricular fibrosis in renovascular hypertensive rats. Effect of losartan and spironolactone. ( Appay, MD; Bariety, J; Heudes, D; Hinglais, N; Michel, JB; Nicoletti, A; Philippe, M; Sassy-Prigent, C, 1995) |
| "Spironolactone, however, was able to prevent myocardial fibrosis in RHT and aldosterone models of acquired arterial hypertension irrespective of the development of LVH and the presence of hypertension." | 1.29 | Antifibrotic effects of spironolactone in preventing myocardial fibrosis in systemic arterial hypertension. ( Brilla, CG; Matsubara, LS; Weber, KT, 1993) |
| "Spironolactone was able largely to prevent the perivascular/interstitial fibrosis and scarring in either model irrespective of the development of left ventricular hypertrophy and arterial hypertension." | 1.28 | Reactive and reparative myocardial fibrosis in arterial hypertension in the rat. ( Brilla, CG; Weber, KT, 1992) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (8.33) | 18.7374 |
| 1990's | 3 (25.00) | 18.2507 |
| 2000's | 2 (16.67) | 29.6817 |
| 2010's | 6 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Singh, PK | 1 |
| Rajput, R | 1 |
| Banerjee, S | 1 |
| Garg, K | 1 |
| Lincevicius, GS | 1 |
| Shimoura, CG | 1 |
| Nishi, EE | 1 |
| Perry, JC | 1 |
| Casarini, DE | 1 |
| Gomes, GN | 1 |
| Bergamaschi, CT | 1 |
| Campos, RR | 1 |
| Ceron, CS | 1 |
| Castro, MM | 1 |
| Rizzi, E | 1 |
| Montenegro, MF | 1 |
| Fontana, V | 1 |
| Salgado, MC | 1 |
| Gerlach, RF | 1 |
| Tanus-Santos, JE | 1 |
| Ibuki, C | 1 |
| Kawamata, H | 1 |
| Seino, Y | 1 |
| Mizuno, K | 1 |
| Suzuki, J | 1 |
| Otsuka, F | 1 |
| Inagaki, K | 1 |
| Tanabe, K | 1 |
| Tsukamoto, N | 1 |
| Miyoshi, T | 1 |
| Nakamura, E | 1 |
| Ogura, T | 1 |
| Kumagai, I | 1 |
| Makino, H | 1 |
| Maule, S | 1 |
| Bertello, C | 1 |
| Rabbia, F | 1 |
| Milan, A | 1 |
| Mulatero, P | 1 |
| Milazzo, V | 1 |
| Papotti, G | 1 |
| Veglio, F | 1 |
| Karagiannis, A | 1 |
| Tziomalos, K | 1 |
| Dona, K | 1 |
| Pyrpasopoulou, A | 1 |
| Kartali, N | 1 |
| Athyros, V | 1 |
| Zamboulis, C | 1 |
| Okada, T | 1 |
| Nagai, M | 1 |
| Taniguchi, I | 1 |
| Kuno, M | 1 |
| Imamoto, S | 1 |
| Seki, S | 1 |
| Taniguchi, M | 1 |
| Mochizuki, S | 1 |
| Ogawa, K | 1 |
| Hara, A | 1 |
| Matsunaga, M | 1 |
| Pak, CH | 1 |
| Konishi, T | 1 |
| Kawai, C | 1 |
| Nicoletti, A | 1 |
| Heudes, D | 1 |
| Hinglais, N | 1 |
| Appay, MD | 1 |
| Philippe, M | 1 |
| Sassy-Prigent, C | 1 |
| Bariety, J | 1 |
| Michel, JB | 1 |
| Brilla, CG | 2 |
| Matsubara, LS | 1 |
| Weber, KT | 2 |
12 other studies available for spironolactone and Hypertension, Renovascular
| Article | Year |
|---|---|
Unilateral renal artery stenosis presenting as acute flaccid paralysis: a rare presentation.
Topics: Antihypertensive Agents; Diagnosis, Differential; Humans; Hyperaldosteronism; Hypertension, Renovasc | 2018 |
Aldosterone Contributes to Sympathoexcitation in Renovascular Hypertension.
Topics: Actins; Aldosterone; Animals; Antihypertensive Agents; Arterial Pressure; Baroreflex; Disease Models | 2015 |
Spironolactone and hydrochlorothiazide exert antioxidant effects and reduce vascular matrix metalloproteinase-2 activity and expression in a model of renovascular hypertension.
Topics: Animals; Antioxidants; Aorta; Blood Pressure; Drug Therapy, Combination; Hydrochlorothiazide; Hypert | 2010 |
Successful blood pressure control with additive administration of eplerenone, an aldosterone receptor blocker, in a patient with bilateral renovascular hypertension treated with angioplasty.
Topics: Adult; Angioplasty; Eplerenone; Female; Humans; Hypertension, Renovascular; Mineralocorticoid Recept | 2010 |
Effects of eplerenone on nephrotic syndrome in a patient with renovascular hypertension.
Topics: Amlodipine; Antihypertensive Agents; Dihydropyridines; Eplerenone; Humans; Hypertension, Renovascula | 2011 |
Ventricular repolarization before and after treatment in patients with secondary hypertension due to renal-artery stenosis and primary aldosteronism.
Topics: Adrenalectomy; Adult; Aged; Angioplasty; Blood Pressure; Electrocardiography; Female; Heart Ventricl | 2011 |
Bilateral renal artery stenosis and primary aldosteronism in a diabetic patient.
Topics: Adrenal Glands; Arteriosclerosis; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Humans; | 2005 |
Combined treatment with valsartan and spironolactone prevents cardiovascular remodeling in renovascular hypertensive rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Cardiovascular Physiological Phenomena; Hypertensi | 2006 |
Angiotensin II analogue infusion test in renovascular hypertension under low sodium intake and under spironolactone administration: is angiotensin II analogue infusion test useful in determining the mode of treatment?
Topics: Adolescent; Adult; Blood Pressure; Diet, Sodium-Restricted; Humans; Hypertension, Renovascular; Male | 1984 |
Left ventricular fibrosis in renovascular hypertensive rats. Effect of losartan and spironolactone.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Biochemical Phen | 1995 |
Antifibrotic effects of spironolactone in preventing myocardial fibrosis in systemic arterial hypertension.
Topics: Aldosterone; Angiotensin II; Animals; Cardiomyopathies; Fibrosis; Hyperaldosteronism; Hypertension; | 1993 |
Reactive and reparative myocardial fibrosis in arterial hypertension in the rat.
Topics: Aldosterone; Angiotensin II; Animals; Cardiomegaly; Collagen; Disease Models, Animal; Fibrosis; Hype | 1992 |